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One-pot methodWe have developed methods involving the use of alternate, safer reagents for the scalable syntheses of
the potent BET bromodomain inhibitor JQ1. A one-pot three step method, involving the conversion of
a benzodiazepine to a thioamide using Lawesson’s reagent, followed by amidrazone formation and instal-
lation of the triazole moiety furnished JQ1. This method provides good yields and a facile puriﬁcation pro-
cess. For the synthesis of enantiomerically enriched (+)-JQ1, the highly toxic reagent diethyl
chlorophosphate, used in a previous synthesis, was replaced with the safer reagent diphenyl chlorophos-
phate in the three-step one-pot triazole formation without effecting yields and enantiomeric purity of
(+)-JQ1.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The bromodomain (BRD) proteins are an important class of his-
tone reader proteins that recognize acetylated lysine residues
(KAc) on histone tails and direct transcription complexes to turn
on genes.1 The bromodomain motif is short with approximately
110 amino acids that are conserved in several human genes.2 The
human genome encodes 61 BRDs, which are present in 46 diverse
proteins.3 Crystal structures of BRDs from more than 20 different
proteins demonstrated that bromodomains share a conserved deep
hydrophobic pocket formed by a left-handed four-helical bundle
(aA, aB, aC, aZ) and loop regions of various lengths (ZA and
BC),3,4 which constitute an attractive pocket for the development
of selective protein–protein interaction inhibitors. Among the eight
BRD families, the BRD and BET proteins have been found to be
tractable for drug discovery. Chemical inhibition of BET proteins
exerts a broad spectrum of desirable biological effects such as anti-
cancer, anti-inﬂammatory, and male contraceptive properties.1,5
Triazolothienodiazepine (+)-JQ1 is one of the ﬁrst selective inhi-
bitors with nanomolar afﬁnity for BET proteins (BRD2, BRD3, BRD4
and BRDT).6 The discovery of this potent, selective, and permeable
inhibitor for BETs has stimulated research activity in diverse
therapeutic areas, particularly in oncology, inﬂammation, and viral
infection. Two other BET inhibitors I-BET7627,8 and OTX0155
(Fig. 1) that share the JQ1 scaffold are in clinical trials for the
treatment of NUT midline carcinoma (a rare cancer caused byBRD4-NUT fusions), acute myeloid leukemia, Burkitt’s lymphoma,
and multiple myeloma.6,9,10 (+)-JQ1 also served as a probe to
validate testis-speciﬁc BRDT as a promising reversible male
contraceptive agent.11
As a part of our collaborative efforts to discover non-hormonal
male contraceptive agents, we required a signiﬁcant quantity of
(+)-JQ1 for further evaluations. To meet the demand of (+)-JQ1,
we developed a scalable and safer route to JQ1 based on reported
methods. The reported synthesis that is shown in Scheme 1 pro-
vides racemic JQ1, although the synthesis employs the L-amino
acid (Fmoc-Asp-(OtBu)-OH) (2). Racemization was observed at
several different stages of the synthesis, including the peptide cou-
pling, the aminoketone cyclization, and the thionation.6 Scheme 2
details the synthesis of enantiomerically enriched (+)-JQ1 with 90%
optical purity. While both methods provide short and efﬁcient
methods for the synthesis of JQ1, we were concerned about the
large scale use of excess P2S5 for the conversion of amide 5 to
Scheme 1. Filippakopoulos et al. method for the synthesis of (±)-JQ1.6
Scheme 2. Filippakopoulos et al. method for the synthesis of enantiomerically enriched (+)-JQ1.6
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the conversion of intermediate 5 to (+)-JQ1 (Scheme 2). Excess P2S5
is problematic during work-up because of H2S gas evolution. This
gas is challenging to trap on a large scale, and possesses a noxious,
sulfur-related odor. In addition, the reagent diethyl chlorophos-
phate used in the conversion of amide 5 to (+)-JQ1 (Scheme 2) is
classiﬁed as possessing acute oral, dermal, and inhalation
toxicities.
Results and discussion
In our efforts to circumvent H2S associated issues for thioamide
formation, we replaced P2S5 (4 equiv) with Lawesson’s reagent
(0.5 equiv) for thionation. Initially, 1 mmol of amide 5, prepared
by methods shown in Scheme 1, was treated with Lawesson’s
reagent in reﬂuxing toluene to afford thioamide 6 in 75% yield
(Scheme 3). Although thionation proceeded efﬁciently on a 1 mmol
scale, it provided only a moderate yield (50%) on a larger scale.
Because of the presence of poorly soluble byproducts, puriﬁcation
of this reaction was difﬁcult and required multiple columnScheme 3. Thionation of amide 5 with Lawesson’s reagent.puriﬁcations to obtain pure thioamide 6. While we were pursuing
the reaction with Lawesson’s reagent Zhang et al. reported12 a
similar JQ1 synthesis using Lawesson’s reagent for amide thiona-
tion. They observed moderate yields, analogous to our results.
Next we aimed at optimizing a scalable strategy for the synthe-
sis of JQ1. To achieve this, we designed a one-pot strategy13 for the
conversion of amide 5 to JQ1. Our one-pot strategy (Scheme 4)
started with the treatment of amide 5 with Lawesson’s reagent
in THF at 80 C for 2 h (monitored by TLC), followed by the addition
of excess hydrazine hydrate (10 equiv) at 0 C. The reaction mix-
ture was stirred for 30 min (monitored by TLC) to yield amidrazone
7, which was used for the next step directly after aqueous work-up.
Amidrazone 7 was heated to 110 C for 2 h in a mixture ofScheme 4. Synthesis of (±)-JQ1 via a one-pot method.
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pound (±)-JQ1 in 60% yield over three steps. We found that the
newly designed one-pot strategy (thionation and amidrazone for-
mation) greatly minimized sulfur related concerns (the strong,
unpleasant odor of sulfur byproducts). The puriﬁcation process
was also facile and the reaction proceeded with a slightly improved
overall yield of 60% compared to the reactions in Scheme 1 (55%
overall yield). Using this efﬁcient method we have synthesized
30 g of (±)-JQ1. The reaction was carried out in four batches to
minimize sulfur-related odors but can in principle be performed
on a larger scale. A related approach for the synthesis of bromod-
omain inhibitors involving Lawessons’s reagent was disclosed in
a recent patent.13
Our next goal was to prepare enantiomerically enriched JQ1,
according to the procedure that has been reported by
Filippakopoulos et al. (Scheme 2).6 A concern about the reported
method is the use of highly toxic diethyl chlorophosphate for the
installation of the triazole ring from amide 5 on a larger scale.
We thus investigated alternate conditions to replace the highly
toxic diethyl chlorophosphate and found that the less toxic diphe-
nyl chlorophosphate (corrosive) was equally reactive to activate
the amide functionality and led to the formation of (+)-JQ1 in
excellent yields without effecting enantiomeric purity. To the best
of our knowledge, there are no previous examples in the literature
for the use of diphenyl chlorophosphate for a triazole synthesis.
Following the reported method (Scheme 2), benzodiazepine 5
was prepared and then treated with KOtBu and diphenyl
chlorophosphate to form phosphorylimidate. 8 (Scheme 5), which
was not isolated and subsequently reacted with acetylhydrazide at
room temperature for 1 h followed by heating at 90 C to furnish
enantiomerically enriched (+)-JQ1 in 82% yield. The enantiopurity
of (+)-JQ1 was determined by chiral HPLC. A 91:9 ratio of the
two enantiomers was observed, which is the same as was previ-
ously reported for the synthesis of enantioenriched (+)-JQ1
(Scheme 1).6
In conclusion, we have developed methods involving the use of
alternate, safer reagents for the synthesis of racemic and enan-
tioenriched JQ1.14 We examined the conversion of amide 5 to
thioamide 6 using Lawesson’s reagent and were able to develop a
one-pot method for the three-step conversion of amide 5 to race-
mic JQ1. We found that this method signiﬁcantly improved the
puriﬁcation process and provided JQ1 in good yields. For the syn-
thesis of enantiomerically enriched (+)-JQ1 we replaced the highly
toxic diethyl chlorophosphate reagent used in the literature
procedure with the safer reagent diphenyl chlorophosphate in a
three-step one-pot synthesis without affecting the yield and theScheme 5. Synthesis of enantiomerically enriched (+)-JQ1 with diphenyl
chlorophosphate.enantiomeric purity of (+)-JQ1. These methods should be equally
useful to access other BET inhibitors such as I-BET762, OTX015,
and related analogues with the same or similar scaffolds.
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